FILING ANALYSIS · TUESDAY, NOVEMBER 10
HARVARD BIOSCIENCE INC HBIO — 8-K: Results of Operations and Financial Condition
neutral
Harvard Bioscience reported an 8% year-over-year revenue growth in the third quarter, with revenue of $22.2 million, and reaffirmed its full-year 2026 revenue guidance of 3%-5% year-over-year growth. However, the company's net loss increased to $(2.6) million from $(1.2) million in the same period last year, and adjusted EBITDA decreased to $1.8 million from $2.0 million.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →